The FDA's reversal on uniQure hands Huntington's patients their most credible treatment hope in years

uniQure announced Wednesday that the FDA agreed its Phase 1/2 trial data for AMT-130 can serve as the primary basis for accelerated approval in Huntington's disease, ending months of public dispute with the agency and clearing the path for a regulatory submission next year.

This is not just a win for one small biotech; it signals the FDA is willing to accept earlier-stage data for devastating diseases with no existing treatments, which could reshape how other gene therapy developers approach their own approval strategies.

CarMax's margin warning exposes structural pressure across the entire used-car market

CarMax beat earnings estimates in its latest quarter but the stock dropped nearly 9% after the company flagged that gross profit per vehicle fell year-over-year and consumers are increasingly trading down to cheaper cars, a warning that applies well beyond CarMax's own lot.

Carvana, which had posted strong growth numbers of its own, got caught in the same downdraft, falling more than 10%, because when the industry's largest traditional dealer says margins are structurally squeezed, no used-car seller is immune.

Fortinet's firewall breach is a credibility problem, not just a security patch

Fortinet disclosed Wednesday that an active campaign is targeting its firewall and VPN devices to harvest login credentials, while independent cybersecurity researchers separately reported that tens of thousands of Fortinet devices used by major companies globally have already been compromised.

For a company whose entire business proposition is keeping attackers out of corporate networks, being the attack surface is a reputational wound that no software update fully heals.